ATE217909T1 - Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper - Google Patents

Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper

Info

Publication number
ATE217909T1
ATE217909T1 AT93904304T AT93904304T ATE217909T1 AT E217909 T1 ATE217909 T1 AT E217909T1 AT 93904304 T AT93904304 T AT 93904304T AT 93904304 T AT93904304 T AT 93904304T AT E217909 T1 ATE217909 T1 AT E217909T1
Authority
AT
Austria
Prior art keywords
inhibitor
antibody
cell adhesion
metastasis
production
Prior art date
Application number
AT93904304T
Other languages
English (en)
Inventor
Jyunko Hashino
Shinzo Oikama
Hiroshi Nakazato
Toshihiro Nakanishi
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE217909T1 publication Critical patent/ATE217909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT93904304T 1992-02-14 1993-02-12 Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper ATE217909T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5955192 1992-02-14
PCT/JP1993/000182 WO1993016193A1 (en) 1992-02-14 1993-02-12 Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same

Publications (1)

Publication Number Publication Date
ATE217909T1 true ATE217909T1 (de) 2002-06-15

Family

ID=13116505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904304T ATE217909T1 (de) 1992-02-14 1993-02-12 Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper

Country Status (9)

Country Link
US (1) US5648078A (de)
EP (1) EP0584368B1 (de)
JP (1) JP3483556B2 (de)
AT (1) ATE217909T1 (de)
DE (1) DE69331942T2 (de)
DK (1) DK0584368T3 (de)
ES (1) ES2177540T3 (de)
PT (1) PT584368E (de)
WO (1) WO1993016193A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503462A (ja) * 1998-02-12 2002-02-05 マクギル ユニバーシティ Ｃｅａ／ｎｃａに基づいた癌分化療法
EP1554309A2 (de) * 2002-10-03 2005-07-20 McGILL UNIVERSITY Antikörper und zyklische peptide, die cea ("carcinoembryonic antigen") binden und ihre verwendung als therapeutika gegen krebs
AU2011252699B2 (en) * 2010-05-11 2015-09-17 Governing Council Of The University Of Toronto The N-domain of carcinoembryonic antigen and compositions, methods and uses thereof
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
JPH0811075B2 (ja) * 1982-06-30 1996-02-07 雄治 松岡 単クローン性抗ｃｅａ抗体
JP2607492B2 (ja) * 1987-01-14 1997-05-07 サントリー株式会社 ヒト癌胎児性抗原
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH05119037A (ja) * 1991-08-08 1993-05-14 Suntory Ltd ヒト癌胎児性抗原の免疫測定法

Also Published As

Publication number Publication date
ES2177540T3 (es) 2002-12-16
US5648078A (en) 1997-07-15
DE69331942D1 (de) 2002-06-27
JP3483556B2 (ja) 2004-01-06
EP0584368A4 (en) 1996-07-03
WO1993016193A1 (en) 1993-08-19
EP0584368A1 (de) 1994-03-02
DE69331942T2 (de) 2002-10-02
PT584368E (pt) 2002-10-31
EP0584368B1 (de) 2002-05-22
DK0584368T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
AU563644B2 (en) Hydroxy substituted peptides
DE69414115D1 (de) Vitamin d analoge
ATE150975T1 (de) Peripheralisierung hämatopoietischer stammzellen
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
DE3586697T2 (de) Aktive thymopentin-analoga.
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ATE34077T1 (de) Hautbehandlungsmittel.
ATE217909T1 (de) Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper
ATE361980T1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
DE68911776T2 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE69132159D1 (de) Merosin, dafür kodierende nukleinsäuren, fragmente und deren verwendung
ATE183385T1 (de) Lyopilisierte, wirkstoffhaltige emulsion
ATE156364T1 (de) Verwendung von lectinen für die behandlung von krankheiten
ES8707114A1 (es) Procedimiento para la obtencion de un anticuerpo monoclonal anti-alfa-amilasa
TR199801102T2 (xx) Antineoplazmik peptitler
ATE310083T1 (de) Deprenyl induziertes protein
DE69617255T2 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
MX9606108A (es) Anticuerpos monoclonales contra cd44v6.
IT9067037A0 (it) Sedile o piattaforma che puo' essere movimentato per far seguire al corpo il ritmo di una musica.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
IT8004839A0 (it) Macchina particolarmente adatta per la vendemmia ed il diraspamento dell'uva.
SU782330A1 (ru) Арил-(2-оксиэтиламино)-(4-антипирил)-метаны, проявляющие противовоспалительную активность

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee